Quarterly ResultAug 12, 2026, 07:33 AM
Altimmune Initiates MASH Phase 3, Reports Positive AUD Phase 2 Data
AI Summary
Altimmune, Inc. announced its second quarter 2026 financial results and provided a corporate update, highlighting significant progress in its clinical pipeline. The company initiated the global PERFORMA Phase 3 trial for pemvidutide in MASH and reported positive topline data from the RECLAIM Phase 2 trial in Alcohol Use Disorder (AUD). Additionally, patient enrollment was completed for the RESTORE Phase 2 trial in Alcohol-associated Liver Disease (ALD). As of June 30, 2026, Altimmune held $519 million in cash, cash equivalents, and investments.
Key Highlights
- Initiated global PERFORMA Phase 3 trial for pemvidutide in MASH, with 52-week data anticipated in 2029.
- Reported positive topline data from RECLAIM Phase 2 trial in AUD, meeting primary and key secondary endpoints.
- Completed patient enrollment in RESTORE Phase 2 trial for pemvidutide in ALD, with topline data expected in H2 2027.
- Cash, cash equivalents, and investments totaled $519 million as of June 30, 2026.
- Net loss for Q2 2026 was $22.8 million, or $0.12 per share, compared to $22.1 million in Q2 2025.
- Research and development expenses increased to $18.7 million in Q2 2026 from $17.2 million in Q2 2025.
- General and administrative expenses rose to $7.6 million in Q2 2026 from $5.7 million in Q2 2025.
- Pemvidutide received Breakthrough Therapy Designation for MASH and Fast Track designation for MASH and AUD.
Price Impact
More from ALT